selpercatinib
eli lilly
['libretto-001', 'solid tumor']
#asco22 attendees we re presenting a trial update from libretto-001 on tumor agnostic efficacy of a selective ret inhibitor in patients with ret fusion+ solid tumors. view presentation details here: 
US healthcare providers’ home for emerging science from Lilly Oncology and Loxo Oncology at Lilly. Please see our community guidelines: https://t.co/1q8vAe63mK